Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modified release tacrolimus.

M Roy First1, William E Fitzsimmons

  • 1Research and Development, Fujisawa Healthcare, Inc., Three Parkway North, Deerfield, IL 60015-2548, USA. roy_first@fujisawa.com

Yonsei Medical Journal
|January 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic needs in solid organ transplant recipients: The American Society of Transplantation patient survey.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025
Same author

Comparing the prognostic performance of iBOX and biopsy-proven acute rejection for long-term kidney graft survival.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2024
Same author

Quantifying Clinical Trial Diversity in Pivotal Registration Trials of FDA Novel Drug Approvals.

Therapeutic innovation & regulatory science·2023
Same author

Applying propensity methods to the United States transplant registry for external real-world evidence control arms for 5-year survival in the BENEFIT study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2023
Same author

Qualifying a Novel Clinical Trial Endpoint (iBOX) Predictive of Long-Term Kidney Transplant Outcomes.

Transplant international : official journal of the European Society for Organ Transplantation·2023
Same author

Qualifying a novel clinical trial endpoint (iBOX) predictive of long-term kidney transplant outcomes.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2023
Same journal

The Role of YouTube as an Information Platform for Ovarian Cancer: the Educational Quality and Reliability.

Yonsei medical journal·2026
Same journal

Bone Bridge Effect for the Treatment of Acute Osteoporotic Vertebral Compression Fractures: A Multistrategic Approach Using an Anabolic Agent.

Yonsei medical journal·2026
Same journal

Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy.

Yonsei medical journal·2026
Same journal

The Risk of Incident Diabetes Mellitus in Relation to Egg Consumption among Working-Aged Korean Adults.

Yonsei medical journal·2026
Same journal

SpyGlass Direct Visualization System: A Cost-Effective Approach Enhancing Nutritional and Immune Recovery in Difficult Bile Duct Stone Management.

Yonsei medical journal·2026
Same journal

Optimizing Antibiotic Use for Urinary Tract Infections: A Qualitative Assessment of Regular Prescribing Practices.

Yonsei medical journal·2026
See all related articles

Modified Release tacrolimus offers similar exposure to Prograf but with reduced peak levels. Stable kidney and liver transplant patients can safely switch to once-daily MR tacrolimus, potentially improving compliance.

Area of Science:

  • Pharmacology
  • Transplantation Medicine
  • Drug Formulation

Background:

  • Tacrolimus (Prograf) is a key immunosuppressant post-transplant.
  • Standard tacrolimus dosing is twice daily (bid).
  • Modified Release (MR) tacrolimus offers once-daily (qd) dosing.

Purpose of the Study:

  • To evaluate pharmacokinetics of MR tacrolimus in transplant recipients.
  • To assess safety and efficacy of converting from Prograf bid to MR tacrolimus qd.
  • To compare exposure and variability between tacrolimus formulations.

Main Methods:

  • Pharmacokinetic studies in stable kidney and liver transplant recipients.
  • Conversion from Prograf bid to MR tacrolimus qd (mg-for-mg daily dose).
  • Analysis of exposure (AUC), trough levels (Cmin), and peak levels (Cmax).

Related Experiment Videos

Main Results:

  • MR tacrolimus qd demonstrated similar exposure (AUC) and trough levels (Cmin) to Prograf bid in healthy volunteers.
  • Steady-state exposure and target trough levels were equivalent after conversion in transplant patients.
  • Significantly less intra-subject variability in exposure was observed with MR tacrolimus.

Conclusions:

  • Stable kidney and liver transplant recipients can be safely converted to MR tacrolimus qd.
  • A mg-for-mg daily dose conversion is effective.
  • Once-daily MR tacrolimus may improve patient compliance while maintaining immunosuppression.